Ovid Therapeutics Inc.
NASDAQ:OVIDBiotechnology
-$0.11 today
- Market cap
- $426.53M
- Beta
- 0.18
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.33
Volume 2.16M
Average 3.07M
OVID Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Ovid Therapeutics Inc.NASDAQ: OVID
Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Investing cash flow growth accelerates
Q1 FY2026 investing cash flow of $5.95M rose 16.6% year over year, ahead of the -224.0% change in trailing-twelve-month investing cash flow. Over 3 fiscal years it compounded at -17.2% a year.
Context
- Investing cash flow amounted to 687.5% of revenue in FY2025, down 8958.1 pp from a year earlier.
- Investing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +16.6% holds above the trailing-twelve-month pace of -224.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (49.85M) USD
- Year-over-year change
- -191.3%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (49.85M) | -191.3% |
| FY2024 | 2024-12-31 | 54.59M | +2215.6% |
| FY2023 | 2023-12-31 | (2.58M) | +97.1% |
| FY2022 | 2022-12-31 | (87.88M) | -4725.0% |
| FY2021 | 2021-12-31 | (1.82M) | — |
Investing Cash Flow vs competitors
How OVID compares with its peers on the latest reported figures
- OVID's LTM Mar 2026 investing cash flow of $49.01M is the 8th largest of the 11 companies compared; the peer median is $33.06M.
- Its year-over-year change of -224.0% is the lowest of 11, against a peer median of +135.4%.
- Investing cash flow amounts to 688.1% of revenue for OVID, versus a peer median of 60.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $179.25M | +363.9% | — | — | |
| LTM Mar 2026 | $149.75M | +44.2% | +59.7% | 466.8% | |
| LTM Mar 2026 | $106.01M | +152.9% | — | — | |
| LTM Mar 2026 | $105.78M | +488.7% | — | 727.5% | |
| LTM Mar 2026 | $92.35M | +117.8% | — | 253.0% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $78.39M | +0.1% | +364.4% | — |
| LTM Mar 2026 | $67.11M | +773.0% | — | 10.0% | |
| LTM Mar 2026 | $49.01M | -224.0% | -17.2% | 688.1% | |
| LTM Mar 2026 | $4.66M | -16.4% | -55.0% | 5.8% | |
| LTM Jun 2026 | $3.32M | +902.4% | -71.1% | 60.5% | |
| LTM Mar 2026 | $981.99K | +43.1% | -17.0% | 1.4% | |
| Peer median (excluding OVID) | $33.06M | +135.4% | -17.0% | 60.5% | |
Competitors are the stored peer set for OVID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 119.84M | (54.17M) | (52.34M) | (26.43M) | (17.41M) |
| Depreciation & Amortization | 237K | 1.38M | 1.6M | 613K | 273K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 6.56M | 7.29M | 6.28M | 4.81M |
| Change in Working Capital | (16.81M) | (8.23M) | 2.39M | (150K) | (4.1M) |
| Accounts Receivables | 141.76K | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.7M | (5.17M) | 1.75M | (512K) | (1.23M) |
| Other Working Capital | (18.66M) | (3.06M) | 635.51K | 362K | (2.87M) |
| Other Non-Cash Items | 15.35M | (764.94K) | (4.71M) | (36.26M) | (21.9M) |
| Operating Cash Flow | 118.61M | (55.23M) | (45.78M) | (55.96M) | (38.33M) |
| Capital Expenditures | (189.41K) | (1.42M) | (137.46K) | (71K) | 0 |
| Acquisitions (Net) | (1.63M) | (2.5M) | (10M) | 0 | 0 |
| Purchases of Investments | (1.63M) | (172.96M) | (112.44M) | (73.25M) | (91.85M) |
| Sales of Investments | 0 | 90M | 120M | 128M | 42M |
| Other Investing Activities | (5.4K) | (1M) | (97.15K) | (89K) | 0 |
| Investing Cash Flow | (1.82M) | (87.88M) | (2.58M) | 54.59M | (49.85M) |
| Debt Repayment | 0 | 0 | 30M | 0 | 0 |
| Common Stock Issued | 925.4K | 180.66K | 535.2K | 622K | 75.21M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (21.31K) | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 904.08K | 180.66K | 30.54M | 622K | 75.21M |
| Effect of Forex Changes | (1.93M) | 0 | 0 | 0 | (167K) |
| Net Change in Cash | 115.76M | (142.93M) | (17.83M) | (740K) | (13.15M) |
| Free Cash Flow | 118.42M | (56.65M) | (45.92M) | (56.03M) | (38.33M) |
Ovid Therapeutics Inc.
NASDAQ:OVID
Intrinsic Alpha fair value
Locked
Current Price
$2.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.